Scithera key facts
as of Oct 2026- Developer of noval antibody design for drug conjugates.based in California .
- Scithera is valued at approximately $60.0M as of Oct 2026 (last reported valuation).
- It has raised $26.0M; the latest was Early Stage VC ($26.0M) in May 2025.
- Notable investors include Venrock.
- Status: Privately Held (backing).
Scithera's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Scithera: the Monday email on marks, rounds and moves
Scithera funding rounds
No funding rounds for Scithera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Scithera
1Scithera valuation
Scithera's last reported valuation was $60 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Scithera investors
1 investor is on record for Scithera, including Venrock. By type, the record holds 1 venture capital firm.
About Scithera
Developer of noval antibody design for drug conjugates.based in California . The company is currently operating in stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- SAN DIEGO, CA, United States
- Founded
- 2025
- Website
- scithera.bio/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.